PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-2.79%
Both yoy net incomes decline, with AGEN at -44.82%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-4.72%
Both reduce yoy D&A, with AGEN at -5.63%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-4.68%
Negative yoy SBC while AGEN is 1.34%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
284.52%
Well above AGEN's 24.44% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
299.08%
AP growth well above AGEN's 104.87%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-348.88%
Negative yoy usage while AGEN is 154.04%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
208.62%
Lower 'other non-cash' growth vs. AGEN's 421.29%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
35.18%
Some CFO growth while AGEN is negative at -46.15%. John Neff would note a short-term liquidity lead over the competitor.
82.00%
CapEx growth well above AGEN's 26.64%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.00%
Investing outflow well above AGEN's 26.55%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.